Drug intelligence / Profile preview

valproate + haloperidol

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Valproate + haloperidol is a combination of two pharmaceutical drugs used together for the treatment of acute mania in bipolar I disorder, and has also been studied as adjunct therapy in schizophrenic psychoses. **Valproate** is primarily an anticonvulsant and mood stabilizer that increases central nervous system levels of gamma-aminobutyric acid (GABA), reducing neuronal excitability and stabilizing mood. **Haloperidol** is a typical antipsychotic that antagonizes dopamine D2 receptors, providing antimanic and antipsychotic effects. When used together, the combination can be effective for controlling manic symptoms in bipolar I disorder, though safety concerns (adverse events, extrapyramidal symptoms) require close monitoring. Clinical studies indicate the combination is effective but may lead to increased adverse effects, such as extrapyramidal symptoms and metabolic changes, compared to other antipsychotic combinations[1][2][3].

Brand names
Haldol + valproate sodium
Other names
valproic acid + haloperidol
02

Targets

NaV (Voltage-gated sodium channels)HDAC (HDAC family)DRD2 (Dopamine D2 Receptor)GABA (Gamma-aminobutyric acid)

Beyond the preview

Go deeper on valproate + haloperidol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on valproate + haloperidol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call